Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN / PEA-PME eligible), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces Invus Public Equities LP converted into ordinary shares all the convertible bonds it had subscribed for in June 2019.
“We are very pleased with the solid progress achieved in 2019 led by the strong management team of Sensorion. A number of significant milestones were achieved: 2 successful financing rounds strengthened the financial position of the company, the scientific platform was enhanced by securing the landmark broad gene therapy agreement with Institut Pasteur and the clinical development of SENS-401 moved forward. Now, with a stronger balance sheet the company is able to attract great talents to build its pipeline. Invus is fully committed to supporting Sensorion’s ambition to become a global leader in the inner ear space, leveraging its unique platform to bring innovative treatments for patients. With the conversion of our convertible bonds, we strongly reiterate our confidence in Sensorion’s team and we look forward to exciting developments in 2020 with multiple catalysts ahead for SENS-401 and the gene therapy programs”, states Khalil Barrage, Partner at Invus
Invus Public Equities LP converted into ordinary shares of the Company all of the 12,500,000 convertible bonds (“CBs”) it had subscribed for in June 2019. The conversion of these CBs has been undertaken in accordance with the terms of the CBs on the basis of a reference price corresponding to the lower of (a) €1.3662, and (b) the volume weighted average of the prices of the trading sessions during a three-month period ending on the trading day preceding the conversion request date, i.e. €0.76. The number of ordinary shares issued by the Company as a result of such conversion is 16,447,368 and these new ordinary shares will be listed on Euronext Growth on the same trading line as the existing ordinary shares (ISIN Code FR0012596468). Following the conversion of the CBs, Invus Public Equities LP holds 20,591,259 ordinary shares of the Company, representing 42.29% of the share capital and voting rights of the Company.
New capital structure
Before conversion of the convertible bonds | After conversion of the convertible bonds | On a fully diluted basis | |||||
Number of shares | Capital Ownership | Number of shares | Capital Ownership | Number of shares | Capital Ownership | ||
Inserm Transfert Initiative | 982,911 | 3.05% | 982,911 | 2.02% | 982,911 | 1.61% | |
Innobio (Bpifrance) | 3,499,874 | 10.85% | 3,499,874 | 7.19% | 3,499,874 | 5.74% | |
Management, employees, directors(1)(4)(5) | 221,582 | 0.69% | 221,582 | 0.46% | 1,817,493 | 2.98% | |
Cochlear | 533,755 | 1.66% | 533,755 | 1.10% | 533,755 | 0.88% | |
Invus (OC 0624)(2) | 4,143,891 | 12.85% | 20,591,259 | 42.29% | 20,591,259 | 33.80% | |
Sofinnova (OC 0624)(3) | 1,953,837 | 6.06% | 1,953,837 | 4.01% | 11,822,258 | 19.40% | |
New Investors (September 2019 capital raise) | 9,489,051 | 29.43% | 9,489,051 | 19.49% | 9,489,051 | 15.57% | |
Free Float (including former officers and directors)(5) | 11,422,362 | 35.42% | 11,422,362 | 23.46% | 12,192,741 | 20.01% | |
Total | 32,247,263 | 100.00% | 48,694,631 | 100.00% | 60,929,343 | 100.00% | |
Assumptions
Before conversion of Invus convertible bonds:
| |||||||
About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases enabling it to select the best targets and modalities for drug candidates. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion has launched in the second half of 2019 two preclinical gene therapy programs aiming at correcting hereditary monogenic forms of deafness including Usher Type 1 and deafness caused by a mutation of the gene encoding for Otoferlin. The Company is uniquely placed through its platforms and pipeline of potential therapeutics to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders; a significant global unmet medical need.
www.sensorion-pharma.com
Label : SENSORION
ISIN : FR0012596468
Mnemonic : ALSEN
Disclaimer
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the ‘Document de référence’ registration document filed with the ‘Autorité des Marchés Financiers’ (AMF French Financial Market Authority) on September 7th, 2017 under n°R.17-062 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200209005028/en/
Contacts:
Catherine Leveau
catherine.leveau@sensorion-pharma.com
+33 467 207 730
Financial communication
LifeSci Advisors – Sophie Baumont sophie@lifesciadvisors.com
+33 6 27 74 74 49
